{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:12080"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:12080","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Exploring the immune signature of lung adenocarcinoma: examining RORγT expression in KRAS and STK11 mutant tumours","abstract":"Lung adenocarcinoma (LUAD) is a common subtype of non-small-cell lung carcinoma that is driven by somatic mutations in various cancer genes. Intratumoural immunity is linked to tumour genetics and can influence response to treatment. Examining LUAD data from The Cancer Genome Atlas (TCGA), we delineated immune gene expression signatures for tumours with mutations in 11 different key cancer genes including KRAS and STK11. Although both these groups had generally low immune gene expression, each demonstrated significantly increased RORC mRNA expression, which encodes the T helper 17 (Th17) transcription factor RORγT. Using a unique cohort of mutationally profiled tumour resections, we found significantly higher intratumoural RORγT\\(^+\\) lymphocytes by immunohistochemistry in LUADs with these mutations, many of which bordered tertiary lymphoid structures. Multiplex immunohistochemistry revealed that these lymphocytes were largely Th17s, and elevated intratumoural RORγT\\(^+\\) lymphocytes were associated with poor overall survival. We subsequently developed an in vitro system in which T cells were cultured in media conditioned by lung carcinoma cell lines and found suppressed or regulatory CD3\\(^+\\)/CD4\\(^+\\)/RORγT\\(^+\\) T cells were present in conditioned media from cell lines with loss of STK11 function. These findings show that cancer gene mutations can influence tumour immunity and have important implications for stratified immunotherapy.","abstract_html":"Lung adenocarcinoma (LUAD) is a common subtype of non-small-cell lung carcinoma that is driven by somatic mutations in various cancer genes. Intratumoural immunity is linked to tumour genetics and can influence response to treatment. Examining LUAD data from The Cancer Genome Atlas (TCGA), we delineated immune gene expression signatures for tumours with mutations in 11 different key cancer genes including KRAS and STK11. Although both these groups had generally low immune gene expression, each demonstrated significantly increased RORC mRNA expression, which encodes the T helper 17 (Th17) transcription factor RORγT. Using a unique cohort of mutationally profiled tumour resections, we found significantly higher intratumoural RORγT<span class=\"etd-inline-math\"><sup>+</sup></span> lymphocytes by immunohistochemistry in LUADs with these mutations, many of which bordered tertiary lymphoid structures. Multiplex immunohistochemistry revealed that these lymphocytes were largely Th17s, and elevated intratumoural RORγT<span class=\"etd-inline-math\"><sup>+</sup></span> lymphocytes were associated with poor overall survival. We subsequently developed an in vitro system in which T cells were cultured in media conditioned by lung carcinoma cell lines and found suppressed or regulatory CD3<span class=\"etd-inline-math\"><sup>+</sup></span>/CD4<span class=\"etd-inline-math\"><sup>+</sup></span>/RORγT<span class=\"etd-inline-math\"><sup>+</sup></span> T cells were present in conditioned media from cell lines with loss of STK11 function. These findings show that cancer gene mutations can influence tumour immunity and have important implications for stratified immunotherapy.","abstract_has_math":true,"creators":["Buchanan, Richard James"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-12","date_published":"2021-12","updated_at":"2026-11-19T09:31:36Z","subjects":["QR180 Immunology"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/12080/1/Buchanan2021PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A12080","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["Buchanan, Richard James"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2021-12"]},{"key":"dc:date.issued","label":"Date","values":["2021-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/12080/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QR180 Immunology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/12080/1/Buchanan2021PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Lung adenocarcinoma (LUAD) is a common subtype of non-small-cell lung carcinoma that is driven by somatic mutations in various cancer genes. Intratumoural immunity is linked to tumour genetics and can influence response to treatment. Examining LUAD data from The Cancer Genome Atlas (TCGA), we delineated immune gene expression signatures for tumours with mutations in 11 different key cancer genes including KRAS and STK11. Although both these groups had generally low immune gene expression, each demonstrated significantly increased RORC mRNA expression, which encodes the T helper 17 (Th17) transcription factor RORγT. Using a unique cohort of mutationally profiled tumour resections, we found significantly higher intratumoural RORγT\\(^+\\) lymphocytes by immunohistochemistry in LUADs with these mutations, many of which bordered tertiary lymphoid structures. Multiplex immunohistochemistry revealed that these lymphocytes were largely Th17s, and elevated intratumoural RORγT\\(^+\\) lymphocytes were associated with poor overall survival. We subsequently developed an in vitro system in which T cells were cultured in media conditioned by lung carcinoma cell lines and found suppressed or regulatory CD3\\(^+\\)/CD4\\(^+\\)/RORγT\\(^+\\) T cells were present in conditioned media from cell lines with loss of STK11 function. These findings show that cancer gene mutations can influence tumour immunity and have important implications for stratified immunotherapy."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Exploring the immune signature of lung adenocarcinoma: examining RORγT expression in KRAS and STK11 mutant tumours"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["Buchanan, Richard James"],"dc:date":["2021-12"],"dc:date.issued":["2021-12"],"dc:description.abstract":["Lung adenocarcinoma (LUAD) is a common subtype of non-small-cell lung carcinoma that is driven by somatic mutations in various cancer genes. Intratumoural immunity is linked to tumour genetics and can influence response to treatment. Examining LUAD data from The Cancer Genome Atlas (TCGA), we delineated immune gene expression signatures for tumours with mutations in 11 different key cancer genes including KRAS and STK11. Although both these groups had generally low immune gene expression, each demonstrated significantly increased RORC mRNA expression, which encodes the T helper 17 (Th17) transcription factor RORγT. Using a unique cohort of mutationally profiled tumour resections, we found significantly higher intratumoural RORγT\\(^+\\) lymphocytes by immunohistochemistry in LUADs with these mutations, many of which bordered tertiary lymphoid structures. Multiplex immunohistochemistry revealed that these lymphocytes were largely Th17s, and elevated intratumoural RORγT\\(^+\\) lymphocytes were associated with poor overall survival. We subsequently developed an in vitro system in which T cells were cultured in media conditioned by lung carcinoma cell lines and found suppressed or regulatory CD3\\(^+\\)/CD4\\(^+\\)/RORγT\\(^+\\) T cells were present in conditioned media from cell lines with loss of STK11 function. These findings show that cancer gene mutations can influence tumour immunity and have important implications for stratified immunotherapy."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/12080/1/Buchanan2021PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/12080/"],"dc:subject":["QR180 Immunology"],"dcterms:accessrights":["public"],"dc:title":["Exploring the immune signature of lung adenocarcinoma: examining RORγT expression in KRAS and STK11 mutant tumours"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:31:36Z"}